The patient received trifluridine/tipiracil plus bevacizumab as third-line therapy; is currently on month 4 of treatment.​ ...
Orca-T immunotherapy shows promising results in improving survival and reducing complications in patients with hematologic ...
A promising trial reveals pumitamig combined with chemotherapy shows high response rates, suggesting potential benefits for ...
A combination of the antibody-drug conjugate enfortumab vedotin (Padcev) and the PD-1 inhibitor pembrolizumab (Keytruda) ...
Michael Wang, MD, professor at The University of Texas MD Anderson Cancer Center, details the rationale for a long-term ...
PLT012, a groundbreaking anti-CD36 antibody, enters clinical trials to enhance immune responses in solid tumors, promising ...
UCSF's Dr Laura Huppert explores a phase 2 trial assessing ARX788's safety and efficacy for HER2-low breast cancer patients, ...
Schmid detailed the rationale of combining pumitamig and chemotherapy and how the combination can aid patients in the first ...
The blood-based test by Astrin Biosciences shows high sensitivity and specificity across cancer stages and subtypes, ...
The FDA has granted regular approval to rucaparib (Rubraca) for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback